Table 2 Adverse effects
From: Meta-analysis of effect of vernakalant on conversion of atrial fibrillation
Study name | T/C | Adverse events | |
|---|---|---|---|
Type | T/C | ||
Camm 2011 [11] | 116/116 | Monomorphic nonsustained | 1/0 |
ventricular tachycardia | |||
Cardiac arrest | 0/1 | ||
Pratt 2010 [7] | 118/121 | Ventricular tachycardia | 16/13 |
Ventricular fibrillation | 1/0 | ||
Bradycardia | 8/0 | ||
Hypotension | 7/2 | ||
Roy 2004 [12] | 36/20 | Cardiac disorders | 7/7 |
Roy 2008 [8] | 221/115 | Nonsustained ventricular tachycardia | 14/17 |
Bradycardia | 1/0 | ||
Hypotension | 14/4 | ||
Ventricular bigeminy | 1/0 | ||
Uncorrected QT > 550 ms | 1/1 | ||
Stiell 2010 [13] | 229/61 | Any ventricular arrhythmia events | 20/10 |
Ventricular tachycardia | 18/9 | ||
Ventricular extrasystoles | 2/1 | ||
Bradycardia | 21/7 | ||
Hypotension | 20/7 | ||